Overview
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients
Status:
Completed
Completed
Trial end date:
2008-06-01
2008-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteersPhase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- HCV RNA ≥ 100,000 IU/mL at screening
- Genotype 1a or 1b
Exclusion Criteria:
- Current or prior treatment with IFN and/or RBV
- Evidence of decompensated liver disease